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Available online 17 December 2015Ctr9, the key scaffold subunit in human RNA polymerase II associated factor complex (PAFc), has diverse func-
tions in cells and has been implicated in human diseases. Recently, our study found that loss of Ctr9 led to appar-
ent morphological change, decrease of proliferation, and reduced colony formation in ERα+ breast cancer cells.
Moreover, Ctr9 and ERα show positive correlation at protein levels and the high levels of Ctr9 are associated
with poor survival among all women with ERα+ breast cancers, and speciﬁcally among those treated with ta-
moxifen. To gain a molecular understanding of the role of Ctr9 in promoting ERα+ breast cancer, we performed
a microarray gene expression proﬁling of Ctr9-regulated transcriptome. Here we provide the experimental de-
tails and analysis of the microarray data, which have been deposited into Gene Expression Omnibus (GEO):
GSE73388.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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geo/query/acc.cgi?acc=GSE73388.
2. Experimental design, materials and methods
2.1. Cell culture and reagents
MCF7-tet-on-shCtr9 cells were generated and characterized previ-
ously [1,2] and maintained in DMEM supplemented with 10% FBS.
Cells were cultured at 37 °C in a humidiﬁed atmosphere containing 5%Cancer Research, Wisconsin
n, WI 53705, USA.
. This is an open access article underCO2. Doxycycline (Dox) was purchased from Clontech (Mountain
View, CA) and used at a ﬁnal concentration of 500 ng/ml to induce
Ctr9-targeting shRNA expression. Dimethyl sulfoxide (DMSO) and 17
β-estradiol (E2) were purchased from Sigma (St. Louis, MO).
2.2. Ctr9 knockdown and E2 induction
In order to globally identify E2- and Ctr9-regulated transcriptome in
ERα+ breast cancer cells, MCF7-tet-on-shCtr9 cells were maintained in
DMEM supplemented with 10% FBS in the absence or presence of
500 ng/mL Dox for 4 days, followed by continuing culture in stripped
medium with or without 500 ng/ml Dox for another 3 days. Cells were
subsequently treatedwith DMSO or 10 nME2 for 4 h prior to cell collec-
tion (Fig. 1).
2.3. Total RNA extraction and microarray hybridization
To ensure the biological conﬁdence, three independent experiments
were performed as illustrated in Fig. 1. Total RNA from twelve samples
was extracted using a Qiagen RNeasy Plus Kit according to
manufacturer's protocol. The RNA quantity was determined by
NanoDrop spectrophotometer. Puriﬁed total RNA was then submitted
to the University of Wisconsin Madison Biotechnology Center. RNA
quality was assessed on the Agilent 2100 BioAnalyzer using a RNA
6000 Nano Chip. All twelve RNA samples look intact, with both ribo-
somal peaks present (Fig. 2). 400 ng of total RNA for each sample was
used to synthesize double-stranded cDNA and the corresponding
in vitro transcription (IVT) cRNA, using the Ambion WT Expression Kitthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Experimental design for global identiﬁcation of E2- and Ctr9-regulated
transcriptome.
Fig. 2. Assessment of RNA quality on the Agilent 2100 BioAnalyzer.
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bridization quality, 400 ng of polyA control RNA was spiked in for each
sample. Subsequently, cRNA was puriﬁed and quantiﬁed and then sub-
ject to single strand (ss) cDNA synthesis. The puriﬁed ss cDNAwas then
fragmented to b150 bp and end-terminus labeled using Affymetrix
GeneChip WT Terminal Labeling Kit following manufacturer's guide-
lines. The labeled samples were then hybridized to GeneChip Human
Transcriptome Array 2.0 containing N6.0 million distinct probes cover-
ing 44,699 protein coding genes and 22,829 non-protein coding genes
at 45 °C for 16 h, according to the guidelines in the Affymetrix GeneChip
WT Terminal Labeling and Hybridization User Manual.
2.4. Data process and analysis
After hybridization, the GeneChip arrays were washed and then
stained (streptavidin–phycoerythrin) on an Affymetrix Fluidics Station
450 followed by scanning on a GeneChip 3000 G7 Scanner. The scanned
images were analyzed to produce raw data ﬁles saved as CEL ﬁles. Data
analysis and visualization were performed using the Affymetrix
Transcriptome Analysis Console (TAC) Software per the manufacturer's
protocol. The criteria for selecting differentially expressed genes was
1.5-fold change cutoff and a false discovery rate b0.05. Based on this
criteria, we found that over 1600 genes were regulated by estrogen
treatment, and of those 1600, only 50 genes respond to E2 after Ctr9
knockdown, suggesting the essential role of Ctr9 in regulating ERα-
dependent gene transcription [2].
3. Discussion
We described here a dataset composed of microarray gene expres-
sion proﬁling of E2- and Ctr9-regulated genes in MCF7 human breastcancer cells. With this genome-wide transcriptome analysis, we were
able to demonstrate Ctr9, the key scaffold subunit in human PAFc, as a
master-regulator of estrogen signaling in ERα+ breast cancer [2]. We
believe that this dataset would provide valuable information for re-
searchers who are interested in studying the estrogen response hierar-
chy in ERα+ breast cancer.
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